Home/Pipeline/Seqirus mRNA/Cell-based Vaccines

Seqirus mRNA/Cell-based Vaccines

Influenza

Research to Phase 3ActiveN/A

Key Facts

Indication

Influenza

Phase

Research to Phase 3

Status

Active

Company

CSL

About CSL

CSL Limited's mission is to deliver innovative biotherapies and vaccines to patients with serious and rare diseases, leveraging a diversified portfolio and integrated business model. The company has achieved global leadership in plasma-derived therapies and influenza vaccines, underscored by strategic acquisitions like Vifor Pharma and a $1.5 billion U.S. manufacturing expansion. Its strategy centers on deepening expertise in immunology, hematology, and nephrology, driving growth through R&D investment, operational excellence, and geographic expansion to meet rising global demand for its critical therapies.

View full company profile

Therapeutic Areas

Hematology Immunology Nephrology Respiratory Vaccines

Other Influenza Drugs

Drug	Company	Phase	Status
PanCytoVir™ (oral probenecid)	TrippBio	IND Submitted	Active
Mimotopes-004	Mimotopes	Preclinical	Active
Next-Gen / Universal Flu Vaccines	CSL Seqirus	Research / Early Clinical	Active
Oseltamivir 75 mg	MSN Laboratories	Commercial	Active
AI Programme - Influenza	Poolbeg Pharma	Discovery	Active - Target/Candidate ID
Influenza Antibodies	new/era/mabs	Research/Pre-clinical	Active
Influenza Countermeasure Program	DynPort Vaccines	Not Specified	Active
Influenza Vaccine	Medigen	Preclinical	Active
Nasal Influenza Vaccine	Abera Bioscience	Pre-clinical	Active
Zapnometinib (ATR-002)	Atriva Therapeutics	Phase 2	Active
EV25	Eradivir	Pre-clinical	Active
Not Specified	New Amsterdam Sciences	Pre-clinical	Active